BG99074A - Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция - Google Patents

Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция

Info

Publication number
BG99074A
BG99074A BG99074A BG9907494A BG99074A BG 99074 A BG99074 A BG 99074A BG 99074 A BG99074 A BG 99074A BG 9907494 A BG9907494 A BG 9907494A BG 99074 A BG99074 A BG 99074A
Authority
BG
Bulgaria
Prior art keywords
niv
infection
treatment
recombinant human
prevention
Prior art date
Application number
BG99074A
Other languages
Bulgarian (bg)
English (en)
Inventor
Emilio Emini
Anthony Conley
George Mark
L. Johnson
David Pfarr
Original Assignee
Merck & Co. Inc.
Medimmune,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc., Medimmune,Inc. filed Critical Merck & Co. Inc.
Publication of BG99074A publication Critical patent/BG99074A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG99074A 1992-04-01 1994-09-28 Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция BG99074A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (en) 1992-04-01 1993-03-23 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Publications (1)

Publication Number Publication Date
BG99074A true BG99074A (bg) 1995-11-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99074A BG99074A (bg) 1992-04-01 1994-09-28 Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция

Country Status (19)

Country Link
EP (1) EP0577243A3 (cs)
JP (1) JPH06217791A (cs)
KR (1) KR950700761A (cs)
CN (1) CN1081716A (cs)
AU (2) AU3928593A (cs)
BG (1) BG99074A (cs)
CA (1) CA2093099A1 (cs)
CZ (1) CZ239694A3 (cs)
FI (1) FI944561L (cs)
HU (1) HUT70461A (cs)
IL (1) IL105145A0 (cs)
MX (1) MX9301858A (cs)
NO (1) NO943653L (cs)
NZ (1) NZ251582A (cs)
RU (1) RU94045907A (cs)
SK (1) SK116294A3 (cs)
WO (1) WO1993019785A1 (cs)
YU (1) YU22693A (cs)
ZA (1) ZA932308B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220114T3 (es) * 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
JP4922613B2 (ja) * 2003-02-20 2012-04-25 一般財団法人化学及血清療法研究所 モノクローナル抗体製剤の奏効性を向上させる方法
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
WO2015117008A2 (en) * 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
JP6522732B2 (ja) * 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
WO1990015078A1 (en) * 1989-06-05 1990-12-13 Scott Charles F Jr HUMAN MONOCLONAL ANTIBODIES TO HIV-1MN gp 120
EP0535154A4 (en) * 1990-06-15 1993-12-01 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (en) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aamp-1, a protein with local homologies to hiv-1 env and nef proteins

Also Published As

Publication number Publication date
EP0577243A3 (en) 1994-11-02
FI944561A7 (fi) 1994-09-30
RU94045907A (ru) 1996-11-10
FI944561A0 (fi) 1994-09-30
NZ251582A (en) 1997-07-27
JPH06217791A (ja) 1994-08-09
FI944561L (fi) 1994-09-30
YU22693A (sh) 1997-01-08
CA2093099A1 (en) 1993-10-02
AU658987B2 (en) 1995-05-04
CZ239694A3 (en) 1995-07-12
KR950700761A (ko) 1995-02-20
HU9402824D0 (en) 1994-11-28
IL105145A0 (en) 1993-07-08
MX9301858A (es) 1994-03-31
EP0577243A2 (en) 1994-01-05
AU3928593A (en) 1993-11-08
CN1081716A (zh) 1994-02-09
HUT70461A (en) 1995-10-30
NO943653D0 (no) 1994-09-30
NO943653L (no) 1994-11-30
SK116294A3 (en) 1996-11-06
WO1993019785A1 (en) 1993-10-14
AU3563093A (en) 1993-10-07
ZA932308B (en) 1994-09-30

Similar Documents

Publication Publication Date Title
BG99074A (bg) Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
RU2317998C2 (ru) Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии
KR950005327A (ko) 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DK442688A (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
EP0648127A4 (en) SURFACE ANTIGENS OF TYPES I AND II ASSOCIATED WITH STAPHYLOCOCCUS EPIDERMIDIS.
DK0552296T3 (da) Monoklonale antistoffer fra mus
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
DK0550020T3 (da) Monoklonale antistoffer mod human-igE
ATE264388T1 (de) Umgestaltete monoklonale antikörper gegen ein immunglobulinisotyp
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
DE69738965D1 (de) Detoxifizierung durch intramuskulär verabreichte F(ab')2 Fragmente
ATE518884T1 (de) Spezifisch an chemokin beta-4 bindende antikörper
BG96346A (bg) Специфични свързващи вещества
ES2150937T3 (es) Autotaxina: proteina estimulante de la motilidad util en el diagnostico y terapia del cancer.
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
EP0321094A3 (en) Treatment of factor viii inhibitors
RU93054302A (ru) Рекомбинантный lgg-связывающий g белок стрептококка группы g